Pfizer Inc.
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
The current standard of care in the treatment of first-line mRCC is combination immunotherapy with or without tyrosine kinase inhibitors. In this setting, therapy management and/or adverse-event management are important components of care that may improve outcomes for patients with RCC. Understanding adverse event etiology especially when overlapping toxicities are a concern may be an important consideration when treating first-line mRCC.
Projects that will be considered for Pfizer support will focus only on two areas:
1. Nursing or pharmacist education programs or resources that nurses or pharmacists can use as they care for patients with RCC
2. Patient education programs or resources that patients can use as they make decisions about their own care and treatment
Grant Application due date: March 22, 2022